{"id":1067893,"date":"2020-11-22T13:59:34","date_gmt":"2020-11-22T18:59:34","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/amarin-shares-topline-data-from-partners-pivotal-phase-3-study-of-vascepa-icosapent-ethyl-in-mainland-china\/"},"modified":"2024-08-18T11:40:37","modified_gmt":"2024-08-18T15:40:37","slug":"amarin-shares-topline-data-from-partners-pivotal-phase-3-study-of-vascepa-icosapent-ethyl-in-mainland-china","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/amarin-shares-topline-data-from-partners-pivotal-phase-3-study-of-vascepa-icosapent-ethyl-in-mainland-china.php","title":{"rendered":"Amarin Shares Topline Data from Partner\u2019s Pivotal Phase 3 Study of VASCEPA\u00ae (Icosapent Ethyl) in Mainland China"},"content":{"rendered":"<p><![CDATA[Significant Reduction in Triglyceride Levels Without Low-Density Lipoprotein Cholesterol (LDL-C) Increase Compared to Placebo and Safety Profile Similar to Placebo Achieved with 4 Grams Per Day Dose of Icosapent Ethyl in Chinese Patients with Very High Triglycerides (>500 mg\/dL)]]><\/p>\n<p>Read the rest here:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"http:\/\/www.globenewswire.com\/news-release\/2020\/11\/19\/2130631\/0\/en\/Amarin-Shares-Topline-Data-from-Partner-s-Pivotal-Phase-3-Study-of-VASCEPA-Icosapent-Ethyl-in-Mainland-China.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Amarin Shares Topline Data from Partner\u2019s Pivotal Phase 3 Study of VASCEPA\u00ae (Icosapent Ethyl) in Mainland China\">Amarin Shares Topline Data from Partner\u2019s Pivotal Phase 3 Study of VASCEPA\u00ae (Icosapent Ethyl) in Mainland China<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> 500 mg\/dL)]]>  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/amarin-shares-topline-data-from-partners-pivotal-phase-3-study-of-vascepa-icosapent-ethyl-in-mainland-china.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1067893","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1067893"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1067893"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1067893\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1067893"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1067893"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1067893"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}